Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
981-1000 of 1,782 trials

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Buprenorphine for Severe Suicidal Thoughts in Major Depression

We are studying whether buprenorphine can help reduce severe suicidal ideas in individuals with major depressive episodes. The trial will compare different doses to find the most effective and safest option.

Clinical Depression≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPsychiatry

Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

Chronic Depression: Ketamine Treatment Study

We are investigating whether adding ketamine to a therapy for chronic depression can reduce symptoms more effectively than a placebo. This study aims to help improve treatment options for those struggling with depression.

Chronic Depression≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Depression: Pramipexole for Anhedonia Symptoms

We are studying whether pramipexole can help reduce anhedonia symptoms in people with depression. The trial will also look at its effects on overall mood, physical activity, and sleep quality.

AnhedoniaMajor DepressionConfirmation phase (III)Standard MedicinesPsychiatry

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Botox for Inability to Belch

We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.

Esophageal Disorders>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyOtolaryngology

Major Depressive Disorder: Ketamine and ECT Study

We are investigating whether combining ketamine with electroconvulsive therapy helps people with treatment-resistant depression. The study also examines its effects on brain chemicals and cognitive function.

Treatment Resistant DepressionMajor Depressive Disorder1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPsychiatry

Wheezing in Young Children: Oral Prednisolone Study

We are investigating whether oral prednisolone helps children under 2 years old with wheezing caused by rhinovirus. This study aims to find out if it improves their breathing and overall comfort.

Rhinovirus-induced WheezingMonitoring phase (IV)Standard MedicinesPediatricsPulmonology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology